BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus

-
Investigator: Mandana Khalili, MD
Sponsor: Bristol-Myers Squibb Company

Location(s): Mexico; Argentina; Puerto Rico; Australia

Description

The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and Ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and Ribavirin alone.